Benzinga's Top Downgrades

Analysts at Goldman Sachs downgraded

from Buy to Neutral. The target price for Cisco has been lowered from $35 to $32. Cisco shares fell 1.59 percent to $28.50 in pre-market trading. Morgan Stanley downgraded

from Overweight to Equal-weight. The target price for Infinity Pharmaceuticals has been lowered from $11 to $1. Infinity Pharmaceuticals shares dipped 6.62 percent to $1.27 in pre-market trading. Analysts at RBC Capital downgraded

from Outperform to Sector Perform. The target price for LinkedIn has been raised from $160 to $196. LinkedIn shares gained 0.06 percent to $191.75 in pre-market trading. H.C. Wainwright downgraded

from Buy to Neutral. The target price for United Therapeutics has been lowered from $175 to $95. United Therapeutics shares declined 2.21 percent to $104.89 in pre-market trading. Analysts at JMP Securities downgraded

from Market Outperform to Market Perform. Marketo shares rose 0.03 percent to close at $35.06 on Tuesday. Credit Suisse downgraded

from Outperform to Neutral. The target price for Tesoro has been lowered from $100 to $90. Tesoro shares dropped 0.59 percent to $72.28 in pre-market trading. Analysts at KeyBanc downgraded

from Overweight to Sector Weight. Compass Minerals shares rose 0.32 percent to close at $78.34 on Tuesday. Avondale Partners downgraded

from Market Outperform to Market Perform. The target price for Broadridge Financial is set to $65. Broadridge Financial shares dropped 0.48 percent to close at $63.97 on Monday. Cowen & Company downgraded

from Outperform to Market Perform. LDR Holding shares rose 0.16 percent to $36.96 in pre-market trading. Barrington Research downgraded

from Outperform to Market Perform. Cimpress shares fell 0.73 percent to $93.28 in pre-market trading.